Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Class action law

This article was originally published in The Tan Sheet

Executive Summary

A bill granting federal jurisdiction over state class action suits with claims of $5 mil. or more was signed by President Bush Feb. 18 after clearing the House Feb. 17. The law is the first successful step in the Administration's broad tort reform agenda, but medical and product liability may be a tougher sell (1"The Tan Sheet" Jan. 10, 2005, p. 9)...

You may also be interested in...



Liability Reform Foes Point To COX-2s, Attack “FDA Defense”

COX-2 safety concerns have provided opponents of "FDA defense" provisions with a weapon against medical liability legislation as President Bush launches a campaign for his tort reform agenda

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Topics

UsernamePublicRestriction

Register

PS097866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel